Eloxx Pharmaceuticals (ELOX) Given Consensus Rating of “Buy” by Brokerages

Eloxx Pharmaceuticals (OTCMKTS:ELOX) has been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $22.20.

Several analysts have issued reports on the company. Zacks Investment Research upgraded Eloxx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 15th. HC Wainwright assumed coverage on Eloxx Pharmaceuticals in a research note on Monday, December 24th. They issued a “neutral” rating and a $10.00 price objective on the stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in Eloxx Pharmaceuticals by 6.0% during the fourth quarter. Bank of New York Mellon Corp now owns 67,111 shares of the company’s stock worth $806,000 after purchasing an additional 3,800 shares during the last quarter. BlackRock Inc. lifted its stake in Eloxx Pharmaceuticals by 36.9% during the fourth quarter. BlackRock Inc. now owns 1,493,471 shares of the company’s stock worth $17,938,000 after purchasing an additional 402,501 shares during the last quarter. Rhumbline Advisers lifted its stake in Eloxx Pharmaceuticals by 51.5% during the fourth quarter. Rhumbline Advisers now owns 28,562 shares of the company’s stock worth $343,000 after purchasing an additional 9,707 shares during the last quarter. Vanguard Group Inc lifted its stake in Eloxx Pharmaceuticals by 60.0% during the third quarter. Vanguard Group Inc now owns 857,202 shares of the company’s stock worth $14,606,000 after purchasing an additional 321,328 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Eloxx Pharmaceuticals by 60.0% during the third quarter. Vanguard Group Inc. now owns 857,202 shares of the company’s stock worth $14,606,000 after purchasing an additional 321,328 shares during the last quarter.

OTCMKTS:ELOX opened at $11.21 on Tuesday. Eloxx Pharmaceuticals has a 12-month low of $6.25 and a 12-month high of $24.60.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Recommended Story: What impact do institutional investors have on markets?

Analyst Recommendations for Eloxx Pharmaceuticals (OTCMKTS:ELOX)

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply